Here's a look at what MarketWatch staffers and readers consider to be 2023's most talked-about stocks and the key issues that will drive their performances.
Medicare's exclusion of weight-loss drug coverage is coming under scrutiny amid mounting evidence that Wegovy and similar drugs have health benefits beyond.